Fort Washington Investment Advisors Inc. OH Acquires 2,274 Shares of AbbVie Inc. $ABBV

Fort Washington Investment Advisors Inc. OH raised its stake in shares of AbbVie Inc. (NYSE:ABBV) by 1.1% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 210,990 shares of the company’s stock after purchasing an additional 2,274 shares during the period. Fort Washington Investment Advisors Inc. OH’s holdings in AbbVie were worth $55,193,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Ranch Capital Advisors Inc. grew its stake in shares of AbbVie by 37.0% in the 1st quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock worth $3,238,000 after acquiring an additional 4,017 shares in the last quarter. Capital Advisors Inc. OK lifted its position in shares of AbbVie by 11.2% during the second quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock valued at $112,516,000 after purchasing an additional 45,132 shares in the last quarter. Danica Pension Livsforsikringsaktieselskab bought a new position in shares of AbbVie during the second quarter valued at about $23,557,000. Wedge Capital Management L L P NC boosted its holdings in AbbVie by 7.5% during the second quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock worth $33,865,000 after purchasing an additional 9,380 shares during the last quarter. Finally, Mission Wealth Management LP boosted its holdings in AbbVie by 119.1% during the second quarter. Mission Wealth Management LP now owns 69,052 shares of the company’s stock worth $17,376,000 after purchasing an additional 37,531 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by insiders.

AbbVie Price Performance

NYSE ABBV opened at $283.58 on Thursday. The stock has a market capitalization of $501.03 billion, a price-to-earnings ratio of 80.11, a PEG ratio of 1.25 and a beta of 0.24. AbbVie Inc. has a one year low of $190.75 and a one year high of $285.40. The business’s fifty day moving average is $261.16 and its 200-day moving average is $238.38.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts expect that AbbVie Inc. will post 13.95 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Thursday, October 15th. AbbVie’s payout ratio is presently 195.48%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New Phase 3 AFFIRM data showed subcutaneous SKYRIZI improved clinical and endoscopic outcomes in patients with moderately to severely active Crohn’s disease. The results could support regulatory review of a more convenient formulation and strengthen AbbVie’s post-Humira growth outlook. AbbVie Presents New Phase 3 AFFIRM Data
• Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating and maintained a $280 price target, while Erste Group raised its FY2027 EPS estimate to $16.34 from $16.19 and kept a Buy rating. RBC Reaffirms Outperform Rating
• Positive Sentiment: Unusually heavy call-option activity—86,296 calls purchased, roughly 445% above average volume—signals increased bullish speculative interest, although options activity is not a fundamental indicator.
• Positive Sentiment: Healthcare stocks broadly rallied, providing a favorable sector backdrop. Investors are also looking ahead to AbbVie’s October 30 earnings report, with expectations that Rinvoq, Skyrizi and Vraylar will support revenue growth. Lilly, Merck, AbbVie Stocks Surge

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Piper Sandler increased their price objective on shares of AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. Morgan Stanley lifted their target price on shares of AbbVie from $296.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Rothschild & Co Redburn boosted their target price on AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. BMO Capital Markets boosted their target price on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $225.00 target price (up from $203.00) on shares of AbbVie in a report on Tuesday, June 23rd. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus target price of $277.18.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.